Fecal Microbiota Transplant
BiologicalActive comparator will receive oral capsules form of FMT for 2 days (the day of first ingestion as day 0)
NCT Number: NCT05981430
The emergence of multidrug-resistant organisms (MDROs) has become one of the major threats to the healthcare system in Hong Kong in recent years. The situation is particularly worrisome for carbapenem-resistant Enterobacteriaceae (CRE). Taking Queen Mary Hospital as an example, the number of CRE cases has surged from 24 in year 2014 to 625 in year 2021. The case burden in Hong Kong is therefore substantial when all 43 public hospitals and institutions in Hong Kong are considered. With the widespread use of broad-spectrum antibiotics and active case screening, the number of CRE cases is expected to further increase in an exponential manner.
Given that colonization with MDROs is due to gut dysbiosis from antibiotic use, a normal intestinal microbiota is apparently crucial in protecting hosts from colonization with MDROs including CRE. Fecal microbiota transplantation (FMT), which involves the infusion of stool from a healthy donor to the gastrointestinal (GI) tract of a recipient, has gained popularity in recent years to restore colonic microbial diversity in various diseases associated with gut dysbiosis, e.g. Clostridium difficile (CD) infection, ulcerative colitis and even metabolic diseases. The investigators aim to conduct a double-blind randomized controlled trial to evaluate the benefit of FMT via upper GI delivery (oral capsules) on CRE clearance.
Trial opening soon.
Get Notified18 year–90 year
All sexes
Interventional
Not applicable
CRE colonization is associated with a 16.5% risk of infection with a 10% mortality rate. CRE also poses a tremendous strain on the healthcare cost as well as the medical/nursing manpower. The hospital stay is lengthened by two-fold for CRE-infected cases compared with non-infected cases. CRE carriers frequently have to stay in acute hospitals for extended periods of time after settling their acute illnesses, both because of the logistic infeasibility of them being transferred to rehabilitation units or nursing homes, which are devoid of isolation rooms.
Proactive measures have been implemented in hospitals worldwide to prevent the spread of MDROs, especially to vulnerable individuals. Such measures usually include surveillance culture, contact tracing, isolation of carriers and environmental disinfection. Nevertheless, isolation facilities are not always readily available, particularly in resource-limited regions. In addition, contact isolation may result in various adverse effects on the mental well-being of isolated patients, such as depression, anxiety and anger. Time spent with patients in isolation by healthcare workers is less, with a negative effect on patient safety with an eight-fold increase in the risk of adverse events due to supportive care failure.
There has been a growing interest in extending FMT for the decolonization of CRE. However, most of the studies are limited to case reports or case series with small sample sizes (ranging from 10 to 39 patients) as shown by a recent systematic review. The pooled rate of CRE decolonization is promising at 62.1%. However, a randomized controlled trial (RCT) remains the most optimal study design to investigate the true beneficial effect of FMT on CRE decolonization. FMT via oral capsules has several advantages over upper GI delivery or colonoscopy. First, administration of fecal suspension via a feeding tube may not be acceptable to some patients. Second, colonoscopy carries complications of gut perforation, aspiration, and cardiopulmonary suppression from the use of sedatives, in particular among frail and elder patients. When FMT is given via oral capsules, it can even be administered in an outpatient setting, which could substantially reduce cost and waiting time.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Active comparator will receive oral capsules form of FMT for 2 days (the day of first ingestion as day 0)
Placebo comparator will receive placebo oral capsules FMT for 2 days (the day of first ingestion as day 0)
Time frame: 1 month post-FMT
CRE clearance rate via FMT oral capsules
Time frame: 1 week, 2 week, 3 month, 6 month and 12 month post-FMT
CRE clearance rate post-FMT
Time frame: 1 month, 3 month, 6 month and 12 month post-FMT
All-cause mortality post-FMT
Contact information is provided by the study sponsor or research team.
The University of Hong Kong
Other
Oral Fecal Microbiota Transplant Capsules for Decolonization of Carbapenem-resistant Enterobacteriaceae: a Double-blind Randomized Controlled Trial
Acronym: FMT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07676513
Antibiotic Resistance, Bacterial Infections
Nîmes, Gard, France
View Trial DetailsNCT07160569
Carbapenem-Resistant Enterobacteriaceae Infection
Rome, Roma, Italy
View Trial DetailsNCT06210542
Carbapenem-Resistant Enterobacteriaceae Infection, ECMO
View Trial DetailsNCT04535661
Carbapenem-Resistant Enterobacteriaceae Infection
Shanghai, Shanghai Municipality, China
View Trial Details